November is Family Caregivers Month

November is National Family Caregivers Month, a time to recognize and support family caregivers. For individuals managing hepatitis B, caregiving can be especially challenging, requiring careful monitoring of the disease and treatment adherence. It's vital to recognize the role of caregivers in ensuring hepatitis B patients receive proper care and support, contributing to better health outcomes.


Let’s honor caregivers this November! 

Dilnora, #BtheVoice Storyteller and Hepatitis B Advocate

 

Recap: International HBV Meeting 2025

This year’s International HBV Meeting took place in Berlin, bringing together researchers, clinicians, patients and advocates. The four-day conference featured cutting-edge studies in hepatitis B and D, new technologies and research methods, and the latest therapeutic developments discussed jointly by scientists and clinicians from around the world.


The meeting provided rich opportunities to network across all career stages, while trainees had a platform to showcase their work. One of the highlights was the Community Forum, which created a valuable space for dialogue among people living with hepatitis B, clinicians, scientists and public health professionals—fostering meaningful exchanges and engagement. A recording of the Forum can be viewed here.


Thank you to all who attended and made this year’s meeting such a success—we had a packed house! We look forward to gathering again next September in Singapore.

nChroma Bio generously donates to the Foundation

Thank You, nChroma Bio!


We extend our heartfelt thanks to nChroma Bio, a genomic medicines company with a lead program in development for chronic hepatitis B for hosting a company auction and for choosing the Hepatitis B Foundation as the beneficiary!


Their generosity—with 91 items donated and HBF swag contributed by our team—raised over $10,000 and will help support our patient engagement programs, which empower and connect individuals and families affected by hepatitis B and hepatitis D.

We’re deeply grateful to the nChroma Bio team for helping advance our mission to improve lives through public health, awareness, advocacy and support.

Featured #BtheVoice storytellers

Stories of strength: Living with hepatitis B and D. Together, these stories remind us of the power of resilience, compassion and community in facing hepatitis.


Dilnora has cared for her sister with hepatitis B—and later hepatitis D—since 2005. That inspired her to focus her studies and career on hepatitis education and advocacy, helping launch support groups in Uzbekistan and the U.S.


Ntow learned she had hepatitis B after experiencing symptoms such as headaches and loss of appetite. Though she faced stigma and isolation, her mother’s support helped her persevere. Now, she focuses on healthy living and encourages others with hepatitis B to seek advice and care for themselves.


Onesphore, from Burundi, discovered he was born with hepatitis B while serving in the military in 2002. Losing several family members to the virus, he was devastated by his diagnosis, which affected his service but strengthened his commitment to awareness and early testing.


LK was diagnosed with hepatitis B in 2017 after falling ill. Newly graduated and struggling financially, he worried about affording treatment and faced stigma that made him hide his condition. His story highlights the urgent need for support and access to affordable care.

Hepatitis B birth dose town hall

Please join us on Nov. 12 for a virtual town hall to explore recent hepatitis B developments from the Advisory Committee on Immunization Practices (ACIP). This event will provide an open forum for a comprehensive Q & A session covering potential ACIP outcomes, the significance of the hepatitis B birth dose and collaborative efforts to guarantee that every child has access to the hepatitis B vaccine.

Join our virtual discussion about:

  • ACIP,
  • Open Q & A and
  • Protecting access.

Wednesday, Nov. 12, 2025 at 3 p.m. EST

HBV-HDV Community Advisory Board protests potential cuts

in U.S. funding for public health and medical research

The Community Advisory Board (CAB) for hepatitis B and Delta, and we in the hepatitis B patient community, find the recent changes by the U.S. government to public health funding and other health policies problematic and life-threatening. In light of the current atmosphere, our voices must be a part of this conversation. It has taken many years for progress to be made in hepatitis B prevention, diagnosis and linkage to care. 

We in the hepatitis B patient community were hopeful for increased attention to be paid to this virus that kills over 800,000 people each year. Please read the full statement from the CAB here.

You're invited: The 2025 Bruce Witte Lecture

Please join us online for the 2025 Bruce Witte Lecture, “HBV: A 60-year journey through history, virology, biomarkers, disease course, and treatment,” presented by Prof. Man-Fung Yuen, J.P., MBBS, MD, PhD, DSc.

Wednesday, Nov. 12, 2025 | 11 a.m. EST | 📍Virtual (Zoom)

Prof. Yuen is Chair Professor at The University of Hong Kong, Chief of the Division of Gastroenterology and Hepatology at Queen Mary Hospital, and internationally recognized as a leading authority on hepatitis B. With more than 630 publications in top medical journals and over 360 lectures delivered worldwide, his groundbreaking work has shaped the global understanding of hepatitis B, C and liver cancer.


You can learn more about Prof. Yuen here.

Don’t miss this opportunity to hear from one of the foremost experts in the field as he shares insights from decades of research and leadership in HBV prevention, biomarkers, disease progression and treatment. Register to attend online here.

New podcast episode now live!

Expanding access to hepatitis B treatment: Breaking barriers in care

In this episode, we speak with Dr. Su Wang, medical director of the Chinese Medical Program at Cooperman Barnabas Medical Center and Medical Advisor to the Hepatitis B Foundation, along with Dr. Thomas Tu, molecular biologist at the Westmead Institute for Medical Research in Australia. Together, they discuss expanding hepatitis B treatment guidelines by broadening eligibility criteria, improving access, reducing loss to follow-up and the importance of including public health and patient perspectives in guideline development. Read their new paper: Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines here.


Please listen to the podcast here.

Dr. Su Wang and Dr. Thomas Tu

Thank you #Run4HepB team

The Hepatitis B Foundation is grateful to be an Official Charity Partner for the 2025 TCS New York City Marathon. We thank the four runners on our #Run4HepB team for their valuable support. Their dedication enables funding for hepatitis B research, increases public awareness and treatment options for patients, their families, health care professionals, scientists and the broader community.


It's not too late to donate. Your support is needed now more than ever to help us continue our vital work in the fight against Hepatitis B.

Welcoming new public health professionals to the team

Stella Dlamini, MPH

Public Health Program Manager

Stella Dlamini has joined the Hepatitis B Foundation as a public health program manager. She will be leading Hepatitis Delta Connect, the Hep B United Philadelphia Coalition and the CHIPO coalition. She completed her Master of Science in Public Health, specializing in infectious disease epidemiology and vaccines, at the Johns Hopkins Bloomberg School of Public Health. Her background also includes working on community health programs in Baltimore and Uganda, where she focused on harm reduction and HIV prevention, respectively. "I'm excited to join HBF and looks forward to supporting the Foundation’s important work towards a Hepatitis B free world," Stella said!

Noah Trudeau, MSPH

Public Health Program Manager

Noah Trudeau is now a public health program manager at the Hepatitis B Foundation, where he supports the African Hepatitis B Advocacy Coalition (ABAC), leads programmatic initiatives for the B Informed Training Hub and contributes to global efforts to advance liver health. He earned bachelor’s degrees in biology and medical humanities from Johns Hopkins University and completed his MSPH at the Bloomberg School of Public Health, with a concentration in International Health Systems. His practicum with Jhpiego in Côte d’Ivoire focused on improving adolescent health and HPV vaccination uptake through human-centered design and implementation research. Noah explained that he is thrilled to support HBF’s efforts to bridge research, policy and advocacy to accelerate progress toward global hepatitis elimination.

B Informed Fall/Winter 2025 newsletter

We are excited to announce that the latest edition of B Informed, our comprehensive Fall/Winter 2025 newsletter, is now readily available for your enjoyment. This issue is packed with insightful content, designed to keep you informed and engaged in the fight against hepatitis B.


Dive into a collection of highlights, including in-depth coverage on the crucial topic of protecting the hepatitis B vaccine, a heartfelt tribute honoring the enduring legacy of Dr. Baruch Blumberg, a recap of our dynamic Storytellers in Action workshop, a comprehensive summary of the recent liver cancer patient conference, an informative global hepatitis B & D Community Advisory Board update and a detailed account of our ongoing efforts to safeguard birth-dose vaccination programs within the U.S.

Please explore the newest

edition by clicking here.

Journal article of the month

Elimination of hepatitis B virus transmission in

an endemic area in Western Alaska


Journal of IJID Regions

December 2025

Click here to access the article.


McMahon BJ, Johnston JM, Kowalski L, Snowball M, et al

The authors of this story include Brian J. McMahon, MD, a member of the Hepatitis B Foundation's Scientific and Medical Advisor Board. They report that the hepatitis B virus (HBV) is endemic in only one area of the U.S, western Alaska, where 90% of the population are Alaska Native (AN) peoples. There "the incidence of hepatocellular carcinoma (HCC) in children was the highest in the world," in the 1970s. In the 1980s, they screened nearly 54,000 AN peoples for HBV infection, gave the HBV vaccine to almost 44,000 HBV seronegative individuals and began vaccinating all newborn babies vaccination. This study examined the impact 40 years later.


Among their findings: "No hepatitis B surface antigen-positive or HCC cases have been identified in AN peoples under 20 since 1993," and they concluded, "Mass population-based vaccination of seronegative persons, with continuing universal newborn immunization, halted transmission of HBV in western Alaska."

  • Nov. 12: Bruce Witte Memorial Lecture (see above)
  • April 10 (2026): Hepatitis B Foundation Gala  
Learn more about our research and education programs at www.hepb.org

The Hepatitis B Foundation is a global nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. Our commitment includes funding focused research, promoting disease awareness, supporting immunization and treatment initiatives, and serving as the primary source of information for patients and their families, the medical and scientific community and the general public.

Facebook  Twitter  Instagram  Youtube